Bionano Genomics, Inc. (BNGO) Financial Statements
Industry: Laboratory Analytical Instruments
In fiscal 2025, Bionano Genomics reported revenue of $28.5M, down 7.4% from $30.8M the year before. Net income was -$26.4M (a -92.6% net margin), or -$4.85 per diluted share. Gross margin was 46.3% and operating margin was -116.9%. Operating activities generated -$16.3M of cash, leaving -$16.3M of free cash flow. At fiscal year end, Bionano Genomics held $73.6M in total assets against $29.2M in total liabilities, including $3.0M of cash and equivalents.
Open the full interactive Bionano Genomics financials → Quarterly statements, key ratios, valuation history and price charts.
Bionano Genomics Key Stats
| Share Price | $1.36 |
|---|---|
| Market Cap | $15.7M |
| Revenue YoY Growth | -7.4% |
| 52-Week Range | $1.06 – $2.12 |
| Shares Outstanding | 11.5 million (basic, 2026 Q2) |
Bionano Genomics Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $8.5M | $18.0M | $27.8M | $36.1M | $30.8M | $28.5M |
| Cost of Goods Sold | $5.7M | $14.1M | $21.9M | $26.6M | $30.4M | $15.3M |
| Gross Profit | $2.8M | $3.9M | $5.9M | $9.6M | $380,000 | $13.2M |
| Operating Income | -$38.6M | -$77.1M | -$131.7M | -$215.2M | -$104.0M | -$33.3M |
| Pre-Tax Income | -$41.1M | -$78.2M | -$130.7M | -$232.4M | -$112.0M | -$26.3M |
| Income Tax | $29,193 | -$5.7M | $1.9M | $62,000 | $33,000 | $67,000 |
| Net Income | -$41.1M | -$72.4M | -$132.6M | -$232.5M | -$112.0M | -$26.4M |
| Diluted EPS | -$234.00 | -$156.00 | -$276.00 | -$408.60 | -$88.13 | -$4.85 |
Bionano Genomics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $7.4M | $8.0M | $6.7M | $8.2M |
| Net Income | -$8.5M | -$7.9M | -$8.3M | -$7.4M |
| Diluted EPS | -$1.59 | -$1.46 | -$0.76 | -$0.64 |
Bionano Genomics Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $38.4M | $24.6M | $5.1M | $17.9M | $9.2M | $3.0M |
| Current Assets | $46.8M | $272.4M | $157.3M | $140.1M | $39.5M | $45.4M |
| Total Assets | $60.4M | $377.1M | $307.5M | $214.4M | $76.7M | $73.6M |
| Current Liabilities | $8.9M | $21.8M | $35.9M | $100.0M | $37.3M | $22.9M |
| Total Long-Term Debt | $16.3M | — | — | — | — | — |
| Total Liabilities | $25.4M | $40.0M | $58.1M | $118.2M | $41.3M | $29.2M |
| Shareholders' Equity | $35.1M | $337.1M | $249.4M | $96.2M | $35.4M | $44.4M |
Bionano Genomics Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$38.3M | -$71.9M | -$124.8M | -$125.2M | -$68.9M | -$16.3M |
| Cash From Investing | -$2.4M | -$278.1M | $82.8M | $24.2M | $73.8M | -$12.7M |
| Cash From Financing | $61.9M | $336.1M | $23.0M | $113.8M | -$13.7M | $24.0M |
| Free Cash Flow | -$38.3M | — | -$124.8M | -$125.2M | -$68.9M | -$16.3M |
Figures from Bionano Genomics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Bionano Genomics financials page for every line item.
Bionano Genomics Company Profile
| Ticker | BNGO |
|---|---|
| Exchange | Nasdaq |
| Industry | Laboratory Analytical Instruments |
| Headquarters | San Diego, California |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001411690 |
Frequently Asked Questions
What was Bionano Genomics' revenue in fiscal 2025?
Bionano Genomics (BNGO) reported revenue of $28.5M for fiscal 2025.
What is Bionano Genomics' annual revenue history?
Bionano Genomics' annual revenue by fiscal year: 2020: $8.5M; 2021: $18.0M; 2022: $27.8M; 2023: $36.1M; 2024: $30.8M; 2025: $28.5M.
What was Bionano Genomics' net income in fiscal 2025?
Bionano Genomics reported net income of -$26.4M for fiscal 2025.
What was Bionano Genomics' earnings per share (EPS) in fiscal 2025?
Bionano Genomics' diluted EPS was -$4.85 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Bionano Genomics generate in fiscal 2025?
Bionano Genomics generated -$16.3M of free cash flow in fiscal 2025.
What was Bionano Genomics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Bionano Genomics reported revenue of $8.2M.
How many shares of Bionano Genomics are outstanding?
Bionano Genomics reported a weighted average of 11.5 million basic shares outstanding in 2026 Q2.
What is Bionano Genomics' market cap?
Based on its latest closing price, Bionano Genomics (BNGO) has a market capitalization of about $15.7M.
When does Bionano Genomics' fiscal year end?
Bionano Genomics' fiscal year end, as registered with the SEC, is December 31.
Where is Bionano Genomics headquartered?
Bionano Genomics lists its business address in San Diego, California in its SEC filings.